Asia Pacific Sglt2 Inhibitors Market Size & Outlook

Name: Asia Pacific Sglt2 Inhibitors Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The sglt2 inhibitors market in Asia Pacific is expected to reach a projected revenue of US$ 4,154.6 million by 2033. A compound annual growth rate of 7.2% is expected of Asia Pacific sglt2 inhibitors market from 2025 to 2033.

Pharmaceuticals
- Metabolic Disorders Treatment
  - SGLT2 Inhibitors Market Outlook

Asia Pacific sglt2 inhibitors drug outlook (Revenue, USD million, 2021-2033)
- Jardiance (Empagliflozin)
- Farxiga (Dapagliflozin)
- Invokana (Danagliflozin)
- Inpefa (Sotagliflozin)
- Qtern (Dapagliflozin/Saxagliptin)
- Other Drug
Asia Pacific sglt2 inhibitors indication outlook (Revenue, USD million, 2021-2033)
- Type 2 Diabetes
- Cardiovascular
- Chronic Kidney Disease (CKD)
- Others
Asia Pacific sglt2 inhibitors distribution channel outlook (Revenue, USD million, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

Asia Pacific Sglt2 Inhibitors Market Size & Outlook

Data Tree

Sign up - it's easy, and free!